Prediction and prevention of type 1 diabetes

Progress, problems, and prospects

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Type 1 diabetes mellitus (T1D) arises from selective immunologically mediated destruction of the insulin-producing β-cells in the pancreatic islets of Langerhans with consequent insulin deficiency. This occurs in genetically susceptible individuals and is a cellular-mediated process, presumably a specific reaction to one or more β-cell proteins (autoantigens), although probably initiated by some environmental factor(s). There is consequent progressive impairment of β-cell function and decline in β-cell mass. A secondary humoral immune response is characterized by the appearance of autoantibodies that serve as markers of the immune damage to β-cells. This insidious T1D disease process evolves over a period of years. The decline in β-cell function and mass is evidenced metabolically by loss of first-phase insulin response to an intravenous glucose challenge, and later by the appearance of impairment in glycemic regulation, manifested as dysglycemia-usually as impaired glucose tolerance, but occasionally as impaired fasting glucose. Ultimately, the clinical syndrome of T1D becomes evident when the majority of β-cells have been destroyed and frank hyperglycemia supervenes. Given this sequence of events, for which it is possible to envision intervention to interdict the process, it is not surprising that much research effort has been expended to identify individuals at risk of the disease.

Original languageEnglish
Pages (from-to)768-771
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume81
Issue number5
DOIs
StatePublished - May 1 2007

Fingerprint

Type 1 Diabetes Mellitus
Insulin
Islets of Langerhans
Glucose
Glucose Intolerance
Autoantigens
Humoral Immunity
Hyperglycemia
Autoantibodies
Fasting
Biomarkers
Research
Proteins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Prediction and prevention of type 1 diabetes : Progress, problems, and prospects. / Skyler, Jay S.

In: Clinical Pharmacology and Therapeutics, Vol. 81, No. 5, 01.05.2007, p. 768-771.

Research output: Contribution to journalArticle

@article{6d98c3db27864d29881e55a060104b0b,
title = "Prediction and prevention of type 1 diabetes: Progress, problems, and prospects",
abstract = "Type 1 diabetes mellitus (T1D) arises from selective immunologically mediated destruction of the insulin-producing β-cells in the pancreatic islets of Langerhans with consequent insulin deficiency. This occurs in genetically susceptible individuals and is a cellular-mediated process, presumably a specific reaction to one or more β-cell proteins (autoantigens), although probably initiated by some environmental factor(s). There is consequent progressive impairment of β-cell function and decline in β-cell mass. A secondary humoral immune response is characterized by the appearance of autoantibodies that serve as markers of the immune damage to β-cells. This insidious T1D disease process evolves over a period of years. The decline in β-cell function and mass is evidenced metabolically by loss of first-phase insulin response to an intravenous glucose challenge, and later by the appearance of impairment in glycemic regulation, manifested as dysglycemia-usually as impaired glucose tolerance, but occasionally as impaired fasting glucose. Ultimately, the clinical syndrome of T1D becomes evident when the majority of β-cells have been destroyed and frank hyperglycemia supervenes. Given this sequence of events, for which it is possible to envision intervention to interdict the process, it is not surprising that much research effort has been expended to identify individuals at risk of the disease.",
author = "Skyler, {Jay S}",
year = "2007",
month = "5",
day = "1",
doi = "10.1038/sj.clpt.6100179",
language = "English",
volume = "81",
pages = "768--771",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Prediction and prevention of type 1 diabetes

T2 - Progress, problems, and prospects

AU - Skyler, Jay S

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Type 1 diabetes mellitus (T1D) arises from selective immunologically mediated destruction of the insulin-producing β-cells in the pancreatic islets of Langerhans with consequent insulin deficiency. This occurs in genetically susceptible individuals and is a cellular-mediated process, presumably a specific reaction to one or more β-cell proteins (autoantigens), although probably initiated by some environmental factor(s). There is consequent progressive impairment of β-cell function and decline in β-cell mass. A secondary humoral immune response is characterized by the appearance of autoantibodies that serve as markers of the immune damage to β-cells. This insidious T1D disease process evolves over a period of years. The decline in β-cell function and mass is evidenced metabolically by loss of first-phase insulin response to an intravenous glucose challenge, and later by the appearance of impairment in glycemic regulation, manifested as dysglycemia-usually as impaired glucose tolerance, but occasionally as impaired fasting glucose. Ultimately, the clinical syndrome of T1D becomes evident when the majority of β-cells have been destroyed and frank hyperglycemia supervenes. Given this sequence of events, for which it is possible to envision intervention to interdict the process, it is not surprising that much research effort has been expended to identify individuals at risk of the disease.

AB - Type 1 diabetes mellitus (T1D) arises from selective immunologically mediated destruction of the insulin-producing β-cells in the pancreatic islets of Langerhans with consequent insulin deficiency. This occurs in genetically susceptible individuals and is a cellular-mediated process, presumably a specific reaction to one or more β-cell proteins (autoantigens), although probably initiated by some environmental factor(s). There is consequent progressive impairment of β-cell function and decline in β-cell mass. A secondary humoral immune response is characterized by the appearance of autoantibodies that serve as markers of the immune damage to β-cells. This insidious T1D disease process evolves over a period of years. The decline in β-cell function and mass is evidenced metabolically by loss of first-phase insulin response to an intravenous glucose challenge, and later by the appearance of impairment in glycemic regulation, manifested as dysglycemia-usually as impaired glucose tolerance, but occasionally as impaired fasting glucose. Ultimately, the clinical syndrome of T1D becomes evident when the majority of β-cells have been destroyed and frank hyperglycemia supervenes. Given this sequence of events, for which it is possible to envision intervention to interdict the process, it is not surprising that much research effort has been expended to identify individuals at risk of the disease.

UR - http://www.scopus.com/inward/record.url?scp=34247264408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247264408&partnerID=8YFLogxK

U2 - 10.1038/sj.clpt.6100179

DO - 10.1038/sj.clpt.6100179

M3 - Article

VL - 81

SP - 768

EP - 771

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -